Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Equity Average: 2018-2025

Historic Equity Average for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $643.7 million.

  • Bicycle Therapeutics' Equity Average fell 24.49% to $643.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.7 million, marking a year-over-year decrease of 24.49%. This contributed to the annual value of $582.0 million for FY2024, which is 81.39% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Equity Average is $643.7 million, which was down 8.65% from $704.6 million recorded in Q2 2025.
  • Bicycle Therapeutics' Equity Average's 5-year high stood at $852.4 million during Q3 2024, with a 5-year trough of $118.8 million in Q1 2021.
  • For the 3-year period, Bicycle Therapeutics' Equity Average averaged around $541.6 million, with its median value being $614.9 million (2024).
  • In the last 5 years, Bicycle Therapeutics' Equity Average skyrocketed by 184.79% in 2022 and then fell by 27.80% in 2023.
  • Bicycle Therapeutics' Equity Average (Quarterly) stood at $258.5 million in 2021, then rose by 8.35% to $280.1 million in 2022, then spiked by 40.46% to $393.5 million in 2023, then soared by 106.38% to $812.0 million in 2024, then decreased by 24.49% to $643.7 million in 2025.
  • Its Equity Average stands at $643.7 million for Q3 2025, versus $704.6 million for Q2 2025 and $766.7 million for Q1 2025.